Managing Post-Approval Obstacles in a Global Market

One of the most significant risks to a product’s success after its initial launch is the lack of regulatory synchronization. When operating across multiple countries, pharma companies often find that “Global” does not mean “Uniform.”

The Challenge of Fragmented Timelines

Approval timelines and implementation periods vary between health authorities. For instance, a manufacturing change approved by the U.S. FDA in 4 months might take 18 months in a different region like Brazil.

• If you implement a change in one market but are still waiting for approval in another, you are forced to manage dual supply chains. This increases the risk of stockouts and inventory mix-ups.
• Building a “regulatory buffer” into your lifecycle plan allows your team to respond to unexpected health authority queries without halting the supply chain.

Common Regulatory Challenges in Post-approval

1. Lack of Harmonization

Despite global efforts, classification systems for “variations” (product changes) remain inconsistent. A minor change in one region may be a major filing in another.

Maintaining multiple versions of a single dossier increases costs and the potential for errors.

2. Divergent Authority Decisions

Health Authorities (HAs) often interpret the same data differently based on local risk tolerances.

Identical submissions can lead to conflicting label requirements or requests for additional local data, requiring companies to manage discrepancies market-by-market.

3. Unique Local Requirements

Unique packaging rules, in-country testing, and specific legal document authentication require organizations to remain highly flexible and locally informed.

4. Variable Implementation Periods

Timelines for approving and adopting changes vary widely across regions.

This creates a “dual inventory” nightmare, where companies must manufacture old and new versions of the same product simultaneously to satisfy different regional timelines.

Building a Strong Post-Approval Regulatory Strategy

• Start with a Holistic, Cross-Functional Plan: Develop a strategy that integrates diverse perspectives and prepares for multiple possible scenarios.
• Identify Key Changes Early: Proactively flag CMC or labelling modifications to reduce downstream challenges and avoid unnecessary delays.
• Establish a Transparent Communication Framework: Ensure clarity and accessibility of information so stakeholders can make informed, timely decisions.
• Enable Data-Driven Decision Making: Provide stakeholders with reliable, easily accessible data to strengthen alignment and support critical regulatory choices.
• Collaborating with experts: With an in-depth knowledge of the specific regulatory environment, regulatory experts can help companies navigate the complexities more effectively.
• Engage Proactively with Regulatory Agencies: Foster early and ongoing dialogue with health authorities to clarify expectations and proactively address potential hurdles